Todd Asset Management LLC decreased its holdings in Grifols, S.A. (NASDAQ:GRFS) by 0.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 957,331 shares of the biotechnology company’s stock after selling 7,169 shares during the quarter. Todd Asset Management LLC owned about 0.14% of Grifols, worth $21,029,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in the business. New York State Common Retirement Fund lifted its position in Grifols, by 3.4% during the third quarter. New York State Common Retirement Fund now owns 1,133,205 shares of the biotechnology company’s stock valued at $24,806,000 after buying an additional 37,157 shares during the period. BNP Paribas Arbitrage SA lifted its position in Grifols, by 7.9% during the third quarter. BNP Paribas Arbitrage SA now owns 31,440 shares of the biotechnology company’s stock valued at $688,000 after buying an additional 2,300 shares during the period. FDx Advisors Inc. lifted its position in Grifols, by 9.8% during the third quarter. FDx Advisors Inc. now owns 49,167 shares of the biotechnology company’s stock valued at $1,076,000 after buying an additional 4,373 shares during the period. Gabelli Funds LLC lifted its position in Grifols, by 945.5% during the third quarter. Gabelli Funds LLC now owns 184,536 shares of the biotechnology company’s stock valued at $4,039,000 after buying an additional 166,886 shares during the period. Finally, GABELLI & Co INVESTMENT ADVISERS INC. lifted its position in Grifols, by 795.2% during the third quarter. GABELLI & Co INVESTMENT ADVISERS INC. now owns 263,175 shares of the biotechnology company’s stock valued at $5,761,000 after buying an additional 233,775 shares during the period. 21.79% of the stock is owned by institutional investors and hedge funds.

Several brokerages have commented on GRFS. Zacks Investment Research lowered Grifols, from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Citigroup Inc. began coverage on Grifols, in a research report on Tuesday, October 31st. They set a “buy” rating for the company. Finally, BidaskClub lowered Grifols, from a “sell” rating to a “strong sell” rating in a research report on Friday, July 28th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company. Grifols, has an average rating of “Hold” and a consensus target price of $24.00.

Shares of Grifols, S.A. (NASDAQ GRFS) traded down $0.34 during trading on Tuesday, reaching $22.80. The company’s stock had a trading volume of 440,400 shares, compared to its average volume of 643,810. The company has a debt-to-equity ratio of 1.69, a current ratio of 3.17 and a quick ratio of 1.39. The stock has a market capitalization of $15,800.52, a price-to-earnings ratio of 21.43, a P/E/G ratio of 1.69 and a beta of 1.07. Grifols, S.A. has a fifty-two week low of $14.33 and a fifty-two week high of $24.20.

WARNING: “Grifols, S.A. (GRFS) Shares Sold by Todd Asset Management LLC” was originally published by Watch List News and is the property of of Watch List News. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.watchlistnews.com/grifols-s-a-grfs-shares-sold-by-todd-asset-management-llc/1702573.html.

Grifols, Company Profile

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.

Institutional Ownership by Quarter for Grifols, (NASDAQ:GRFS)

Receive News & Ratings for Grifols S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols S.A. and related companies with Analyst Ratings Network's FREE daily email newsletter.